Clinical Trials Sponsored by Novo Nordisk A/S

Total 1547 results

Novo Nordisk A/S

Terminated

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

Diabetes | Diabetes Mellitus, Type 1

United Kingdom, United States, Switzerland, France, Germany, Canada
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BOOST™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico, Russian Federation, United Kingdom, Denmark, France, Israel, Australia, Romania
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, France, Sweden, Poland, Turkey, Korea, Republic of, India, South Africa
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)

Congenital Bleeding Disorder | Haemophilia A

United States, Macedonia, The Former Yugoslav Republic of, Serbia, Malaysia, Brazil, Turkey, Lithuania, Russian Federation, Italy, Japan, Poland, Puerto Rico, Taiwan
Novo Nordisk A/S

Completed

Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes (EFFICACY)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Argentina, Thailand, India, Korea, Republic of
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety of Levemir® in Diabetes (PREDICTIVE™)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Israel, Korea, Republic of, Turkey, Italy, Belgium, United Kingdom, Greece, Ireland, Sweden, Denmark, Finland, France, Czech Republic
Novo Nordisk A/S

Terminated

Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom
Novo Nordisk A/S

Completed

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily (TITRATE™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

India, Korea, Republic of, China
Novo Nordisk A/S

Completed

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-6)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Denmark, Sweden, Austria, Germany, Macedonia, The Former Yugoslav Republic of, Slovenia, France, Switzerland, Norway, Spain, Ireland, Finland, Romania
Novo Nordisk A/S

Completed

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Puerto Rico, United Kingdom, Ireland, Germany, Slovenia, Canada, France, Italy, Spain, Netherlands, Slovakia, Romania, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Germany, Netherlands, Argentina, Finland, Serbia, Mexico
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Terminated

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c (LEAD-3)

Diabetes Mellitus, Type 2 | Diabetes

United States, Mexico, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together (LEAD-2)

Diabetes Mellitus, Type 2 | Diabetes

Slovakia, India, Italy, Russian Federation, Spain, Denmark, United Kingdom, Sweden, Belgium, Ireland, Argentina, Hungary, Norway, South Africa, Germany, Croatia, Netherlands, Bulgaria, Australia, Romania
Novo Nordisk A/S

Completed

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Spain, Finland, Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, United Kingdom, Ireland, France, South Africa, Ukraine
Novo Nordisk A/S

Completed

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Netherlands, Hungary, France, Bulgaria, Canada, Romania
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

India, Italy, United Kingdom, Finland, Japan, Argentina, Macedonia, The Former Yugoslav Republic of, Brazil
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Sweden, Norway, Germany, Australia
Novo Nordisk A/S

Completed

A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Delivery Systems

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Argentina, Turkey, Canada, South Africa, Mexico
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial

Menopause | Postmenopausal Vaginal Atrophy
Novo Nordisk A/S

Completed

Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

Cancer | Ovarian Cancer

Germany, France
Novo Nordisk A/S

Completed

Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Completed

Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Poland, Germany, Italy, Hungary, Czech Republic
Novo Nordisk A/S

Completed

Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

India, Macedonia, The Former Yugoslav Republic of, Russian Federation, Turkey, Croatia, Australia, Philippines
Novo Nordisk A/S

Completed

NovoLet® Surveillance Study on Using Human Insulin System in Indonesia

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Indonesia
Novo Nordisk A/S

Completed

Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

Turkey
Novo Nordisk A/S

Completed

Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age

Foetal Growth Problem | Small for Gestational Age

Spain
Novo Nordisk A/S

Completed

Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin

Healthy | Growth Hormone Disorder | Adult Growth Hormone Deficiency

United States
Novo Nordisk A/S

Completed

Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents

Chronic Kidney Disease | Turner Syndrome | Chronic Renal Insufficiency | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Genetic Disorder | Delivery Systems | Foetal Growth Problem | Small for Gestational Age

France
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes (SimpleMix™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Poland, Spain, India, Argentina, China
Novo Nordisk A/S

Completed

Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects

Healthy | Diabetes

Japan
Novo Nordisk A/S

Completed

Safety of Insulin Detemir in Children With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Japan
Novo Nordisk A/S

Completed

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Canada, Australia
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China

Clinical Trials Sponsored by Novo Nordisk A/S

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations